TWI328453B - Use of estradiol valerate in combination with dienogest in order to obtain a multi-stage combined preparation with a total of 28 daily doses for the treatment of dysfunctional uterine bleeding in conjunction with oral contraception - Google Patents
Use of estradiol valerate in combination with dienogest in order to obtain a multi-stage combined preparation with a total of 28 daily doses for the treatment of dysfunctional uterine bleeding in conjunction with oral contraception Download PDFInfo
- Publication number
- TWI328453B TWI328453B TW095137564A TW95137564A TWI328453B TW I328453 B TWI328453 B TW I328453B TW 095137564 A TW095137564 A TW 095137564A TW 95137564 A TW95137564 A TW 95137564A TW I328453 B TWI328453 B TW I328453B
- Authority
- TW
- Taiwan
- Prior art keywords
- stage
- combination
- estradiol valerate
- dienogest
- uterine bleeding
- Prior art date
Links
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 title claims description 15
- 229960004766 estradiol valerate Drugs 0.000 title claims description 15
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 title claims description 7
- 229960003309 dienogest Drugs 0.000 title claims description 7
- 238000011282 treatment Methods 0.000 title description 7
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 title 1
- 206010027514 Metrorrhagia Diseases 0.000 title 1
- 239000000902 placebo Substances 0.000 claims description 11
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 8
- 239000000186 progesterone Substances 0.000 claims description 4
- 229960003387 progesterone Drugs 0.000 claims description 4
- 229940127234 oral contraceptive Drugs 0.000 claims description 3
- 239000003539 oral contraceptive agent Substances 0.000 claims description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 229960005309 estradiol Drugs 0.000 claims description 2
- 229930182833 estradiol Natural products 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims 2
- 210000004291 uterus Anatomy 0.000 claims 1
- 229940005605 valeric acid Drugs 0.000 claims 1
- 208000037853 Abnormal uterine bleeding Diseases 0.000 description 16
- 208000032843 Hemorrhage Diseases 0.000 description 12
- 208000034158 bleeding Diseases 0.000 description 12
- 230000000740 bleeding effect Effects 0.000 description 12
- 229940068196 placebo Drugs 0.000 description 9
- 230000027758 ovulation cycle Effects 0.000 description 6
- 239000000262 estrogen Substances 0.000 description 4
- 230000002175 menstrual effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000016087 ovulation Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 206010046788 Uterine haemorrhage Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 208000007106 menorrhagia Diseases 0.000 description 3
- 229960000417 norgestimate Drugs 0.000 description 3
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 description 3
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 201000006828 endometrial hyperplasia Diseases 0.000 description 2
- 229960002568 ethinylestradiol Drugs 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- VOXZDWNPVJITMN-SFFUCWETSA-N 17α-estradiol Chemical group OC1=CC=C2[C@H]3CC[C@](C)([C@@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-SFFUCWETSA-N 0.000 description 1
- 201000005670 Anovulation Diseases 0.000 description 1
- 206010002659 Anovulatory cycle Diseases 0.000 description 1
- VUUWICXRDSPFFL-WAJSLEGFSA-N C(CC(O)(C(=O)O)CC(=O)O)(=O)O.[C@@H]12CCC(O)[C@@]1(C)CC[C@@H]1C3=C(CC[C@@H]21)C=C(O)C=C3 Chemical compound C(CC(O)(C(=O)O)CC(=O)O)(=O)O.[C@@H]12CCC(O)[C@@]1(C)CC[C@@H]1C3=C(CC[C@@H]21)C=C(O)C=C3 VUUWICXRDSPFFL-WAJSLEGFSA-N 0.000 description 1
- 241000819038 Chichester Species 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030295 Oligomenorrhoea Diseases 0.000 description 1
- 206010036086 Polymenorrhoea Diseases 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000552 anovulation Toxicity 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 229940083544 estradiol 2 mg Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- DXTIKTAIYCJTII-UHFFFAOYSA-N guanidine acetate Chemical compound CC([O-])=O.NC([NH3+])=N DXTIKTAIYCJTII-UHFFFAOYSA-N 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229940053934 norethindrone Drugs 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 230000000624 ovulatory effect Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05022324A EP1787649B1 (de) | 2005-10-13 | 2005-10-13 | Verwendung von Estradiolvalerat in Kombination mit Dienogest zur oralen Therapie der dysfunktionellen uterinen Blutung in Einheit mit einer oralen Kontrazeption |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200731977A TW200731977A (en) | 2007-09-01 |
| TWI328453B true TWI328453B (en) | 2010-08-11 |
Family
ID=35811580
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW095137564A TWI328453B (en) | 2005-10-13 | 2006-10-12 | Use of estradiol valerate in combination with dienogest in order to obtain a multi-stage combined preparation with a total of 28 daily doses for the treatment of dysfunctional uterine bleeding in conjunction with oral contraception |
| TW096100872A TW200829255A (en) | 2005-10-13 | 2007-01-09 | Use of oestradiol in combination with dienogest for the oral treatment of dysfunctional uterine bleeding in conjunction with oral contraception |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW096100872A TW200829255A (en) | 2005-10-13 | 2007-01-09 | Use of oestradiol in combination with dienogest for the oral treatment of dysfunctional uterine bleeding in conjunction with oral contraception |
Country Status (22)
| Country | Link |
|---|---|
| EP (2) | EP1787649B1 (https=) |
| JP (2) | JP5735200B2 (https=) |
| KR (2) | KR101218872B1 (https=) |
| CN (1) | CN101312733A (https=) |
| AR (1) | AR056694A1 (https=) |
| AT (2) | ATE424828T1 (https=) |
| CA (1) | CA2623024C (https=) |
| CL (1) | CL2011000283A1 (https=) |
| CY (2) | CY1110321T1 (https=) |
| DE (2) | DE502005006837D1 (https=) |
| DK (2) | DK1787649T3 (https=) |
| DO (1) | DOP2006000221A (https=) |
| ES (2) | ES2322479T3 (https=) |
| HR (1) | HRP20090256T1 (https=) |
| ME (1) | ME01056B (https=) |
| PE (2) | PE20100090A1 (https=) |
| PL (2) | PL1787649T3 (https=) |
| PT (2) | PT1787649E (https=) |
| SI (2) | SI1787649T1 (https=) |
| TW (2) | TWI328453B (https=) |
| UY (1) | UY29861A1 (https=) |
| WO (1) | WO2007042296A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004019743B4 (de) | 2004-04-20 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens |
| SI1787649T1 (sl) * | 2005-10-13 | 2009-08-31 | Bayer Schering Pharma Ag | Uporaba estradiolvalerata v kombinaciji z dienogestom za oralno terapijo disfunkcionalne maternične krvavitve skupaj z oralno kontracepcijo |
| US8153616B2 (en) | 2005-10-17 | 2012-04-10 | Bayer Pharma Aktiengesellschaft | Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same |
| EP1930010A1 (de) | 2006-10-20 | 2008-06-11 | Bayer Schering Pharma Aktiengesellschaft | Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4429374C1 (de) * | 1994-08-12 | 1996-02-01 | Jenapharm Gmbh | Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente |
| DE19540253C2 (de) * | 1995-10-28 | 1998-06-04 | Jenapharm Gmbh | Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene |
| ATE249222T1 (de) * | 1996-07-26 | 2003-09-15 | Wyeth Corp | Biphasische orale verhuetungsmethode und kit die eine kombination von progestin und eines oestrogens enthalten |
| US6251956B1 (en) | 1998-08-20 | 2001-06-26 | Ortho Pharmaceutical Corporation | Combination progestin oral contraceptive regimen |
| EP1462106A1 (en) * | 2003-03-28 | 2004-09-29 | Pantarhei Bioscience B.V. | Pharmaceutical compositions and kits comprising 17-beta-estradiol and a progesteron for the treatment of gynecological disorders |
| DE102004019743B4 (de) * | 2004-04-20 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens |
| SI1787649T1 (sl) * | 2005-10-13 | 2009-08-31 | Bayer Schering Pharma Ag | Uporaba estradiolvalerata v kombinaciji z dienogestom za oralno terapijo disfunkcionalne maternične krvavitve skupaj z oralno kontracepcijo |
-
2005
- 2005-10-13 SI SI200530672T patent/SI1787649T1/sl unknown
- 2005-10-13 PT PT05022324T patent/PT1787649E/pt unknown
- 2005-10-13 ES ES05022324T patent/ES2322479T3/es not_active Expired - Lifetime
- 2005-10-13 EP EP05022324A patent/EP1787649B1/de not_active Revoked
- 2005-10-13 ME MEP-2009-171A patent/ME01056B/me unknown
- 2005-10-13 AT AT05022324T patent/ATE424828T1/de active
- 2005-10-13 DE DE502005006837T patent/DE502005006837D1/de not_active Expired - Lifetime
- 2005-10-13 PL PL05022324T patent/PL1787649T3/pl unknown
- 2005-10-13 DK DK05022324T patent/DK1787649T3/da active
-
2006
- 2006-10-12 PL PL06806225T patent/PL1933843T3/pl unknown
- 2006-10-12 SI SI200630991T patent/SI1933843T1/sl unknown
- 2006-10-12 JP JP2008534936A patent/JP5735200B2/ja active Active
- 2006-10-12 KR KR1020107014574A patent/KR101218872B1/ko active Active
- 2006-10-12 CN CNA2006800381810A patent/CN101312733A/zh active Pending
- 2006-10-12 KR KR1020087011203A patent/KR20080065651A/ko not_active Ceased
- 2006-10-12 EP EP06806225A patent/EP1933843B1/de active Active
- 2006-10-12 DK DK06806225.6T patent/DK1933843T3/da active
- 2006-10-12 WO PCT/EP2006/009867 patent/WO2007042296A1/de not_active Ceased
- 2006-10-12 DE DE502006008853T patent/DE502006008853D1/de active Active
- 2006-10-12 PE PE2009001256A patent/PE20100090A1/es not_active Application Discontinuation
- 2006-10-12 PE PE2006001241A patent/PE20070555A1/es not_active Application Discontinuation
- 2006-10-12 CA CA2623024A patent/CA2623024C/en active Active
- 2006-10-12 TW TW095137564A patent/TWI328453B/zh active
- 2006-10-12 AT AT06806225T patent/ATE497387T1/de active
- 2006-10-12 ES ES06806225T patent/ES2360302T3/es active Active
- 2006-10-12 PT PT06806225T patent/PT1933843E/pt unknown
- 2006-10-13 DO DO2006000221A patent/DOP2006000221A/es unknown
- 2006-10-13 AR ARP060104489A patent/AR056694A1/es not_active Application Discontinuation
- 2006-10-13 UY UY29861A patent/UY29861A1/es not_active Application Discontinuation
-
2007
- 2007-01-09 TW TW096100872A patent/TW200829255A/zh unknown
-
2009
- 2009-05-05 HR HR20090256T patent/HRP20090256T1/xx unknown
- 2009-06-11 CY CY20091100621T patent/CY1110321T1/el unknown
-
2011
- 2011-02-10 CL CL2011000283A patent/CL2011000283A1/es unknown
- 2011-05-02 CY CY20111100422T patent/CY1111406T1/el unknown
-
2012
- 2012-11-19 JP JP2012253067A patent/JP2013047269A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7177313B2 (ja) | 避妊用組成物および避妊方法 | |
| JP5128743B2 (ja) | ホルモン置換療法用のドロスピレノン | |
| CN112020360B (zh) | 化合物以及它们在缓解绝经相关症状中的用途 | |
| KR102780201B1 (ko) | 월경통 및 생리통의 관리방법 | |
| CN111989105B (zh) | 化合物以及它们在缓解绝经相关症状中的用途 | |
| TWI845496B (zh) | 具有心血管作用降低的避孕組成物 | |
| JPH08510993A (ja) | ホルモン補充方法 | |
| TW200529862A (en) | Extended use combination comprising estrogens and progestins | |
| EP2004200A2 (en) | Methods for prevention and treatment of conditions arising from local estrogen deficiency | |
| KR20150058555A (ko) | 연장된 호르몬성 피임제 투약법에서 파탄성 출혈의 관리 | |
| JP2012516859A (ja) | １７α−エストラジオールを含む、口腔内適用系 | |
| TW473390B (en) | A hormonal pharmaceutical composition for correcting oestrogen deficiencies in menopausal women | |
| TWI328453B (en) | Use of estradiol valerate in combination with dienogest in order to obtain a multi-stage combined preparation with a total of 28 daily doses for the treatment of dysfunctional uterine bleeding in conjunction with oral contraception | |
| Pelissier et al. | Clinical evaluation, dose-finding and acceptability of AERODIOL®, the pulsed estrogen therapy for treatment of climacteric symptoms | |
| US20100190757A1 (en) | Combination preparation for oral contreaception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same | |
| CN101583364A (zh) | 减轻子宫内膜异位的药物制剂 | |
| WO2021229559A2 (en) | Use of combined oral contraceptives containing nomegestrol acetate and estradiol | |
| HK40120208A (zh) | 化合物以及它们在缓解绝经相关症状中的用途 | |
| TW200946542A (en) | New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen | |
| Raynaud et al. | Comparison of the efficacy and tolerability of a new once-a-week matricial estradiol transdermal system (Estrapatch® 40 and Estrapatch® 60) with a twice week system | |
| Lekskulchai et al. | Randomized Comparative Study of 200 and 400 Micrograms Vaginal Misoprostol for Cervical Priming in Nonpregnant Nulliparous Women Undergoing Fractional Curettage | |
| HK1124267A (en) | Use of estradiol valerate or estradiol combined with dienogest for the oral therapy of dysfunctional uterine bleeding in the form of oral contraceptives | |
| SA01210754B1 (ar) | اتحاد صيدلاني من دروسبيرنون drospirenone ممكرن واستروجين estrogen من اجل العلاج كبديل للهرمون | |
| RS50849B (sr) | Upotreba estradiolvalerata i dienogesta za oralno lečenje disfunkcionalnog uterinog krvarenja u kontracepcijskom metodu | |
| TW200942242A (en) | New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen |